N. Niederle
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Lung Cancer Research Studies, Lung Cancer Treatments and Mutations, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial(2014)1,720 cited
- → Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial(2013)1,476 cited
- → Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer(1998)992 cited
- → Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms(2010)165 cited
- → Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders(1992)163 cited
- → Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).(2009)157 cited
- → Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial(2015)153 cited
- → Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer(2010)150 cited
- → Gemcitabine in Patients With Relapsed or Cisplatin-Refractory Testicular Cancer(1999)139 cited
- → Gemcitabine as a Single Agent in the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma(1999)123 cited